ASIA unversity:Item 310904400/80990
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 94286/110023 (86%)
Visitors : 21700554      Online Users : 372
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/80990


    Title: Management Performance Evaluation of Biotechnology and Medicine Industry in Taiwan - An Application of DEA/TOPSIS
    Authors: Hsieh, Hua-En
    Contributors: 經營管理學系碩士在職專班
    Keywords: Biotechnology and medicine industry
    Data envelopment analysis (DEA)
    Technique for order preference by similarity to ideal solution (TOPSIS)
    Date: 2014-06-06
    Issue Date: 2014-09-17 02:34:00 (UTC+0)
    Publisher: Asia University
    Abstract: This study uses the CCR model and BCC model of the Data Envelopment Analysis (DEA) to evaluate and analyze the performance efficiency of the listed, OTC and emerging biotechnology and medicine companies in Taiwan, in terms of overall technical efficiency, pure technical efficiency and scale efficiency. The findings can provide the operators with relative inefficiency with learning examples and references for improvements. In addition, this study combines the DEA and Technique for Order Preference by Similarity to Ideal Solution (TOPSIS) into the DEA/TOPSIS approach. The biotechnology and medicine firms whose efficiency value in the CCR model is equal to 1 were selected to build the performance evaluation model for the operators. The findings can provide the operators and investors with the references for choosing and investing in the biotechnology and medicine firms in the future. The results of this study show that the company enjoying the best performance is ScinoPharm Taiwan Ltd. in the pharmaceutical industry, Jinghua in the medical devices industry, and Grape King Bio Ltd. in the applied biotechnology industry. They can serve as the learning examples for other companies with poor efficiency and references for the investors when choosing and investing in the biotechnology and medicine firms in the future.
    Appears in Collections:[Department of Business Administration] Theses & dissertations

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML297View/Open


    View Licence

    All items in ASIAIR are protected by copyright, with all rights reserved.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback